2011
DOI: 10.1002/ibd.21583
|View full text |Cite
|
Sign up to set email alerts
|

Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy

Abstract: Direct exposure to anti-TNF treatment during pregnancy was not related to a higher incidence of adverse pregnancy outcomes than IBD overall.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
116
1
7

Year Published

2012
2012
2020
2020

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 169 publications
(128 citation statements)
references
References 28 publications
4
116
1
7
Order By: Relevance
“…Nevertheless, Koren et al (19), considered that these results could not be extrapolated to the general population because their results were based on a database that only collected adverse fetal outcomes. Recently a new study has just been published and concludes that direct exposure to anti-TNF treatment during pregnancy was not related to a higher incidence of adverse pregnancy outcomes than IBD overall (20). At this respect, the British Rheumatology Society consider that no firm conclusions can be drawn about the safety of anti-TNF during pregnancy so guidelines which suggest these drugs should be avoided at the time of conception cannot yet be changed (21).…”
Section: Discussionmentioning
confidence: 99%
“…Nevertheless, Koren et al (19), considered that these results could not be extrapolated to the general population because their results were based on a database that only collected adverse fetal outcomes. Recently a new study has just been published and concludes that direct exposure to anti-TNF treatment during pregnancy was not related to a higher incidence of adverse pregnancy outcomes than IBD overall (20). At this respect, the British Rheumatology Society consider that no firm conclusions can be drawn about the safety of anti-TNF during pregnancy so guidelines which suggest these drugs should be avoided at the time of conception cannot yet be changed (21).…”
Section: Discussionmentioning
confidence: 99%
“…To the best of our knowledge, this is the first report in Japan of the use of ADA therapy in a patient with CD during pregnancy. Direct exposure to anti-TNF-α treatment during pregnancy is not associated with a higher incidence of adverse pregnancy outcomes than inflammatory bowel disease overall (11). ADA, a pregnancy category B drug, is also an IgG1 antibody and should therefore have a placental transfer rate similar to that of IFX (10).…”
Section: Discussionmentioning
confidence: 99%
“…Schnitzler et al compared outcomes of 42 pregnancies with direct exposure to anti-TNF treatment (INF n = 35; ADA n = 7) to 23 pregnancies in women later diagnosed with IBD and did not find a higher incidence of adverse pregnancy outcomes [104]. However, the small study size may have prevented adequate statistical strength as there were reports of seven premature deliveries, six low birthweight, one stillbirth and one premature birth from necrotizing enterocolitis.…”
Section: Infliximabmentioning
confidence: 99%